ImClone/Bristol Aim To Expand Erbitux’s Reach To Asia
This article was originally published in The Pink Sheet Daily
Executive Summary
Development partners broker deal with Merck KGaA to bring the first EGFR receptor-inhibiting monoclonal antibody to Japan.
You may also be interested in...
Facing Flat Erbitux Sales, ImClone Talks Up Line Extension, Pipeline Promise
Firm details plans to become “global, fully integrated, pure play antibody company” during 2007 sales and earnings call.
Facing Flat Erbitux Sales, ImClone Talks Up Line Extension, Pipeline Promise
Firm details plans to become “global, fully integrated, pure play antibody company” during 2007 sales and earnings call.
Erbitux Approved As Monotherapy In Metastatic Colorectal Cancer Setting
Labeling for ImClone/Bristol’s epidermal growth factor receptor inhibitor is updated to include survival data as a single agent in colorectal cancer setting.